Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789

Go back to Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Merck & Co. (NYSE: MRK) Delayed: 147.10 +6.17 (4.38%)
Previous Close $140.93    52 Week High $65.46 
Open $144.62    52 Week Low $47.97 
Day High $149.26    P/E 100.07 
Day Low $143.32    EPS $1.47 
Volume 5,845,976